NAPROXEN SODIUM Drug Patent Profile

When do Naproxen Sodium patents expire, and what generic alternatives are available?

Naproxen Sodium is a drug marketed by Bionpharma, Catalent, Onesource Specialty, Patheon Softgels, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hetero Labs Ltd V, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Novelgenix Theraps, Perrigo, Pharmobedient, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sciegen Pharms, Sun Pharm Inds Ltd, Teva, Teva Pharms, Watson Labs, Yichang Humanwell, Amneal Pharms Co, Corepharma, Granules, P And L, Perrigo R And D, and Aurobindo Pharma. and is included in forty-eight NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifteen patent family members in thirteen countries.

The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naproxen Sodium

A generic version of NAPROXEN SODIUM was approved as naproxen sodium; pseudoephedrine hydrochloride by PERRIGO on March 17^th, 2004.

Summary for NAPROXEN SODIUM

International Patents:	15
US Patents:	5
Applicants:	40
NDAs:	48
Finished Product Suppliers / Packagers:	122
Raw Ingredient (Bulk) Api Vendors:	93
Clinical Trials:	107
Drug Prices:	Drug price information for NAPROXEN SODIUM
Drug Sales Revenues:	Drug sales revenues for NAPROXEN SODIUM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NAPROXEN SODIUM
What excipients (inactive ingredients) are in NAPROXEN SODIUM?	NAPROXEN SODIUM excipients list
DailyMed Link:	NAPROXEN SODIUM at DailyMed

See drug prices for NAPROXEN SODIUM

See drug sales revenues for NAPROXEN SODIUM

Recent Clinical Trials for NAPROXEN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Oklahoma	PHASE4
University of Chicago	PHASE4
Endeavor Health	PHASE4

See all NAPROXEN SODIUM clinical trials

Pharmacology for NAPROXEN SODIUM

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for NAPROXEN SODIUM

G02CC	Antiinflammatory products for vaginal administration
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

M01AE	Propionic acid derivatives
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

M02AA	Antiinflammatory preparations, non-steroids for topical use
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for NAPROXEN SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAPROXEN SODIUM	Capsules	naproxen sodium	200 mg	021920	1	2017-11-15

US Patents and Regulatory Information for NAPROXEN SODIUM

NAPROXEN SODIUM is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granules	NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride; naproxen sodium	TABLET;ORAL	213663-001	Sep 24, 2020		OTC	No	No
Novelgenix Theraps	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	207612-001	Nov 16, 2018		DISCN	No	No
Hamilton Pharms	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074106-001	Aug 31, 1993		DISCN	No	No
Purepac Pharm	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074319-002	Mar 20, 1995		DISCN	No	No
Teva	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074198-001	Dec 21, 1993		DISCN	No	No

Expired US Patents for NAPROXEN SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	10,022,344
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	10,028,925
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	9,693,979
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	9,693,978
Bionpharma	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006	11,090,280

International Patents for NAPROXEN SODIUM

See the table below for patents covering NAPROXEN SODIUM around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	1863458
Lithuania	1863458
Denmark	1863458
Canada	2600023	SYSTEME DE SOLVANT DESTINE A AMELIORER LA SOLUBILITE DES AGENTS PHARMACEUTIQUES (SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS)
European Patent Office	3061447	SYSTÈME DE SOLVANT DESTINÉ À AMÉLIORER LA SOLUBILITÉ D'AGENTS PHARMACEUTIQUES (SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS)

Supplementary Protection Certificates for NAPROXEN SODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
0984957	PA2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1411900	300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105
0984957	122012000051	Germany		PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
1411900	122012000052	Germany		PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105

Market Dynamics and Financial Trajectory for Naproxen Sodium

Last updated: February 19, 2026

What is the current market size and growth trend for naproxen sodium?

The global market for naproxen sodium was valued at approximately $380 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of roughly 3.2% from 2023 to 2030. Growth is driven by its use in analgesic, anti-inflammatory, and antipyretic applications, primarily in over-the-counter (OTC) and prescription formats.

Industry reports indicate stable demand in North America and Europe, accounting for over 65% of sales in 2022. Emerging markets in Asia-Pacific show increased consumption, influenced by rising healthcare awareness and increasing access to OTC therapies.

How have regulatory and patent landscapes influenced market exclusivity and competition?

Market exclusivity for naproxen sodium varies by geographical region. In the U.S., the FDA approved OTC formulations in 1994, with patents expiring in the early 2000s. No recent patent protections have buffered major players from generic competition. Consequently, the market is highly commoditized, with leading generics accounting for over 70% of sales.

In the European Union, regulatory licensing is aligned with similar timelines, expiring patents in the late 2000s. Patent expiry has led to numerous generic entrants, intensifying price competition.

What are the main drivers and barriers affecting market growth?

Drivers:

• Growing prevalence of chronic pain, osteoarthritis, and rheumatoid arthritis.
• Consumer preference for OTC pain relievers due to familiarity and perceived safety.
• Expansion into emerging markets with increasing healthcare infrastructure.

Barriers:

• Competition from other NSAIDs, notably ibuprofen and diclofenac.
• Safety concerns over gastrointestinal and cardiovascular adverse effects.
• Regulatory restrictions in specific markets due to safety profiles.

How is the competitive landscape structured?

The market is dominated by generic manufacturers globally, with a few brand-name formulations still present:

• Major generic firms include Teva Pharmaceuticals, Amneal Pharmaceuticals, and Sandoz.
• Brand-name products, such as Aleve (Bayer), maintain market share primarily in OTC channels.
• Price wars and patent expirations have reduced barriers to entry but shifted focus toward formulation innovations and marketing.

What are the financial implications for key stakeholders?

Pharmaceutical companies:

• Margin erosion from price competition for generic naproxen sodium.
• Revenue streams mainly from volume sales in OTC channels.
• Investment focus shifting toward novel NSAID formulations with improved safety profiles.

Investors:

• Stable revenue in mature markets but limited upside given patent expirations.
• Growth potential in emerging regions due to rising demand.
• Market saturation constrains rapid revenue increases.

Manufacturers:

• Emphasize cost-efficient production to maintain margins.
• Explore licensing and co-marketing agreements in expanding markets.

How do pricing strategies vary across regions?

In North America, OTC naproxen sodium prices average $5–$10 per packaging, typically offering 20–50 tablets of 220 mg. In Europe, pricing ranges from €3–€8 per pack, depending on brand or generic. In Asian markets, price points are often below $3 per pack, reflecting lower manufacturing costs and differing regulatory environments.

What is the outlook for innovation and alternative formulations?

While the market is saturated with generic naproxen sodium, research efforts focus on developing formulations with reduced gastrointestinal risk and enhanced bioavailability. Limited pipeline activity is observed given patent expirations and market maturity. Innovations in delivery mechanisms, such as topical gels or patches, are emerging but constitute a small share of the overall market.

Key financial metrics summary:

Parameter	2022 Figures	Notes
Market Size	$380 million	Global, primarily OTC
Growth Rate	3.2% CAGR (2023-2030)	Estimates based on industry reports
Major Players	Teva, Sandoz, Amneal	Dominant in generics
Patent Status	Expired in major regions	Facilitates generic entry
Price Range	$3–$10 per pack	Varies by region and brand

Key Takeaways

• The naproxen sodium market is mature with steady growth driven by aging populations and chronic pain conditions.
• Patent expirations have resulted in a highly genericized landscape, constraining profit margins.
• Competition from other NSAIDs and safety concerns influence market dynamics.
• Emerging markets present opportunities due to increased healthcare access, though pricing pressures persist.
• Innovation in formulations with improved safety profiles is limited, with most R&D efforts centered on generics.

FAQs

1. What factors most significantly influence naproxen sodium’s market growth?
   Increasing prevalence of chronic pain conditions and consumer preference for OTC drugs primarily drive growth.

2. Are there significant patent protections still in place for naproxen sodium?
   Patents expired in major markets like the U.S. and Europe, leading to widespread generic competition.

3. How does safety concern impact market dynamics?
   Safety risks restrict use in certain populations, reducing potential market segments and prompting some innovation in safer formulations.

4. What regions are expected to show the highest growth?
   Asia-Pacific and Latin America are expected to generate higher growth percentages due to expanding healthcare infrastructure and rising purchasing power.

5. What potential exists for new formulations of naproxen sodium?
   Formulations that reduce gastrointestinal and cardiovascular risks are in development; however, market saturation limits profitability prospects.

---

References

[1] Grand View Research. (2023). Naproxen Market Size, Share & Trends Analysis Report.
[2] US Food and Drug Administration. (2022). Over-the-Counter (OTC) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Description.
[3] European Medicines Agency. (2022). Guidelines on the regulation of NSAID products.
[4] IQVIA. (2023). Global OTC Drug Market Report.
[5] Statista. (2023). Over-the-counter pain relief market revenue in North America.